GlaxoSmithKline Plc ended the first quarter with declines in both turnover and operating profit. However the pipeline generated three regulatory approvals in the quarter and the company initiated Phase 3 trials in new products for respiratory syncytial (RSV) virus, asthma, and a prospective vaccine for Covid-19.
